Skip to main content
TryTrutide
Editorial Transparency

Corrections & Update History

TryTrutide is committed to accuracy. When we identify errors or when new evidence changes our understanding, we update affected pages and record the change here. This log covers meaningful corrections and substantive content updates — not routine formatting or typographical fixes.

Our Correction Process

  1. Errors are identified through internal review, reader feedback, or updated primary sources.
  2. The affected page is updated with corrected information.
  3. A correction entry is added to this log with the page, date, reason, and supporting source.
  4. The page's last-reviewed date is updated.

Correction Log

/fda-regulationSeptember 19, 2026

Corrected regulatory status language. Prior version incorrectly stated that an NDA had been accepted by FDA and that a PDUFA target date existed for retatrutide. As of September 2026, no application has been submitted or accepted. Eli Lilly's current public position is that it plans to submit a Biologics License Application (BLA) for retatrutide in Q1 2027. Updated page language to reflect this accurately.

Source: Eli Lilly Q2 2026 Earnings Release — investor.lilly.com

/retatrutide-availabilitySeptember 14, 2026

Added regulatory pathway section and clarified that projected approval dates are company estimates, not confirmed FDA commitments.

Source: Eli Lilly investor relations — investor.lilly.com

/retatrutide-compoundingSeptember 14, 2026

Clarified that retatrutide is not on the FDA shortage list and therefore cannot be legally compounded under 503A or 503B.

Source: FDA Drug Shortages Database — accessdata.fda.gov/scripts/drugshortages/

Report an Error

If you believe a page contains an error, outdated information, or a broken citation, please contact us. Include the page URL, the specific claim you believe is incorrect, and the source you are citing.

Last reviewed: September 19, 2026